Phoenix Financial Ltd. Purchases 7,371 Shares of Boston Scientific Corporation $BSX

Phoenix Financial Ltd. grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 7.0% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 113,278 shares of the medical equipment provider’s stock after buying an additional 7,371 shares during the quarter. Phoenix Financial Ltd.’s holdings in Boston Scientific were worth $12,165,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Boston Scientific by 1.3% during the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after acquiring an additional 1,697,945 shares during the last quarter. Invesco Ltd. increased its position in shares of Boston Scientific by 5.3% during the first quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider’s stock valued at $1,677,124,000 after buying an additional 834,274 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Boston Scientific by 10.8% during the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after buying an additional 1,383,524 shares during the period. Amundi increased its position in shares of Boston Scientific by 2.6% during the first quarter. Amundi now owns 12,308,715 shares of the medical equipment provider’s stock valued at $1,212,408,000 after buying an additional 311,034 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Boston Scientific by 4.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 11,299,942 shares of the medical equipment provider’s stock valued at $1,139,938,000 after buying an additional 460,580 shares during the period. 89.07% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director owned 2,081 shares in the company, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $17,561,336.74. The trade was a 21.90% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 174,214 shares of company stock worth $17,972,457. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX opened at $100.56 on Tuesday. The stock has a market cap of $149.01 billion, a PE ratio of 59.86, a price-to-earnings-growth ratio of 2.39 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The firm’s 50-day simple moving average is $101.25 and its two-hundred day simple moving average is $101.85.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the prior year, the company earned $0.62 earnings per share. The business’s revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Canaccord Genuity Group boosted their price target on shares of Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Royal Bank Of Canada reiterated an “outperform” rating and set a $125.00 price target on shares of Boston Scientific in a research report on Monday, September 29th. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $118.00 to $125.00 in a research report on Monday, September 8th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Finally, Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $120.71.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.